P
The startup develops synthetic molecules for pharmaceutical applications targeting Parkinson's and Alzheimer's diseases. By translating laboratory research into clinical treatments, the company aims to enhance patient care and improve therapeutic outcomes for these neurodegenerative conditions.
San Francisco, United States
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops synthetic molecules for pharmaceutical applications targeting Parkinson's and Alzheimer's diseases. By translating laboratory research into clinical treatments, the company aims to enhance patient care and improve therapeutic outcomes for these neurodegenerative conditions.